256 related articles for article (PubMed ID: 19419238)
1. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N
Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238
[TBL] [Abstract][Full Text] [Related]
2. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs).
Hedenmalm K; Sundström A; Spigset O
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):719-25. PubMed ID: 16783834
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Schifano F
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631391
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
6. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
7. Adverse event reporting with selective serotonin-reuptake inhibitors.
Hartnell NR; Wilson JP; Patel NC; Crismon ML
Ann Pharmacother; 2003 Oct; 37(10):1387-91. PubMed ID: 14519041
[TBL] [Abstract][Full Text] [Related]
8. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.
Kim S; Park K; Kim MS; Yang BR; Choi HJ; Park BJ
Psychiatry Res; 2017 Oct; 256():237-242. PubMed ID: 28646789
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
Edwards JG; Anderson I
Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
[TBL] [Abstract][Full Text] [Related]
11. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
12. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
Price JS; Waller PC; Wood SM; MacKay AV
Br J Clin Pharmacol; 1996 Dec; 42(6):757-63. PubMed ID: 8971432
[TBL] [Abstract][Full Text] [Related]
14. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
Tomlin A; Reith D; Dovey S; Tilyard M
Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
16. Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases.
Humbert X; Fedrizzi S; Chrétien B; Sassier M; Bagheri H; Combret S; Drici MD; Le Bas F; Puddu PE; Alexandre J
Fundam Clin Pharmacol; 2019 Jun; 33(3):296-302. PubMed ID: 30489655
[TBL] [Abstract][Full Text] [Related]
17. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
18. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.
Aagaard L; Hansen EH
BMC Clin Pharmacol; 2009 Mar; 9():4. PubMed ID: 19254390
[TBL] [Abstract][Full Text] [Related]
19. What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
Womersley K; Ripullone K; Agius M
Psychiatr Danub; 2017 Sep; 29(Suppl 3):629-644. PubMed ID: 28953843
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Ray WA; Chung CP; Murray KT; Hall K; Stein CM
J Clin Psychiatry; 2017 Feb; 78(2):190-195. PubMed ID: 27736049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
